1020 patients with knee osteoarthritis were randomized in order to evaluate the efficacy and safety of naproxcinod treatments compared with placebo and conventional nonsteroidal anti-inflammatory drugs (naproxen 500mg). The study primarily assessed patients for efficacy using the WOMAC pain and function subscales along with several long-term secondary measures (including blood pressure,safety and adverse events). The study concluded that naproxcinod at both tested doses of 350mg and 750mg was superior to placebo controls and performed comparably to the naproxen 500mg over a full year of treatment.